Zweegman, Sonja ;
Stege, Claudia A M ;
Haukas, Einar...
Zweegman , S , Stege , C A M , Haukas , E , Schjesvold , F H , Levin , M-D , Waage , A , Leys , R B L , Klein , S K , Szatkowski , D , Axelsson , P , Hieu Do , T , Knut-Bojanowska , D , van der Spek , E , Svirskaite , A , Klostergaard , A , Salomo , M , Blimark , C , Ypma , P F , Mellqvist , U-H , Poddighe , P J , Stevens-Kroef , M , van de Donk , N W C J , Sonneveld , P , Hansson , M , van der Holt , B & Abildgaard , N 2020 , ' Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial ' , Haematologica , vol. 105 , no. 12 , pp. 2879-2882 . https://doi.org/10.3324/haematol.2019.240374.
,
2020
